Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.

Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA, Ryu JH, Seyama K, Inoue Y, Downey GP, Han MK, Colby TV, Wikenheiser-Brokamp KA, Meyer CA, Smith K, Moss J, McCormack FX; ATS Assembly on Clinical Problems.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1337-1348. doi: 10.1164/rccm.201709-1965ST.

2.

Heme Oxygenase-1 Deficiency Diminishes Methicillin-Resistant Staphylococcus aureus Clearance Due to Reduced TLR9 Expression in Pleural Mesothelial Cells.

Gahlot S, Nasreen N, Johnson JA, Sahn SA, Mohammed KA.

PLoS One. 2017 Jan 4;12(1):e0169245. doi: 10.1371/journal.pone.0169245. eCollection 2017.

3.

Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; ATS/JRS Committee on Lymphangioleiomyomatosis.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61. doi: 10.1164/rccm.201607-1384ST.

4.

Pleural Fluid Analysis in Chronic Hemothorax: A Mimicker of Infection.

DiVietro ML, Huggins JT, Angotti LB, Kummerfeldt CE, Nestor JE, Doelken P, Sahn SA.

Clin Med Insights Case Rep. 2015 Aug 10;8:71-6. doi: 10.4137/CCRep.S12404. eCollection 2015.

5.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Respir Med. 2015 Jul;109(7):914-22. doi: 10.1016/j.rmed.2015.04.008. Epub 2015 Apr 24.

6.

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW.

Chest. 2015 Jul;148(1):196-201. doi: 10.1378/chest.14-2817.

7.

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205.

PMID:
25363219
8.

Characteristics of patients with yellow nail syndrome and pleural effusion.

Valdés L, Huggins JT, Gude F, Ferreiro L, Alvarez-Dobaño JM, Golpe A, Toubes ME, González-Barcala FJ, José ES, Sahn SA.

Respirology. 2014 Oct;19(7):985-92. doi: 10.1111/resp.12357. Epub 2014 Aug 14. Review.

9.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM.

Respirology. 2014 Jul;19(5):740-7. doi: 10.1111/resp.12297. Epub 2014 May 18.

10.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.

N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.

11.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

12.

6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.

13.

Improving the predictive accuracy of identifying exudative effusions.

Kummerfeldt CE, Chiuzan CC, Huggins JT, DiVietro ML, Nestor JE, Sahn SA, Doelken P.

Chest. 2014 Mar 1;145(3):586-592. doi: 10.1378/chest.13-1142.

PMID:
24008773
14.

Viral diseases affecting the pleura.

Nestor J, Huggins T, Kummerfeldt C, DiVietro M, Walters K, Sahn S.

J Clin Virol. 2013 Oct;58(2):367-73. doi: 10.1016/j.jcv.2013.06.013. Epub 2013 Aug 1. Review.

PMID:
23916378
15.

Pulmonary capillaritis in a patient with moderately positive anti-PL-12 antibodies.

Kummerfeldt CE, Huggins JT, Riemer EC, Ravenel JG, Whelan TP, Sahn SA.

Int J Rheum Dis. 2013 Apr;16(2):233-4. doi: 10.1111/1756-185X.12058. Epub 2013 Apr 4. No abstract available.

PMID:
23773650
16.

Can tuberculous pleural effusions be diagnosed by pleural fluid analysis alone?

Sahn SA, Huggins JT, San José ME, Álvarez-Dobaño JM, Valdés L.

Int J Tuberc Lung Dis. 2013 Jun;17(6):787-93. doi: 10.5588/ijtld.12.0892.

PMID:
23676163
17.

Effects of coexisting pneumonia and end-stage renal disease on pleural fluid analysis in patients with hydrostatic pleural effusion.

Doelken P, Huggins JT, Goldblatt M, Nietert P, Sahn SA.

Chest. 2013 Jun;143(6):1709-1716. doi: 10.1378/chest.12-2221.

18.

More pearls afoot.

Heffner JE, Sahn SA, Harding SM.

Chest. 2013 Jan;143(1):5-7. doi: 10.1378/chest.12-1985. No abstract available.

PMID:
23276836
19.

Parasitic diseases of the pleura.

Lal C, Huggins JT, Sahn SA.

Am J Med Sci. 2013 May;345(5):385-9. doi: 10.1097/MAJ.0b013e318266e984. Review.

PMID:
22990049
20.

Unusual bacterial infections and the pleura.

Kummerfeldt CE, Huggins JT, Sahn SA.

Open Respir Med J. 2012;6:75-81. doi: 10.2174/1874306401206010075. Epub 2012 Sep 6.

21.

Getting the most from pleural fluid analysis.

Sahn SA.

Respirology. 2012 Feb;17(2):270-7. doi: 10.1111/j.1440-1843.2011.02100.x. Review.

PMID:
22059482
22.

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22.

23.

Intrapleural therapy.

Huggins JT, Doelken P, Sahn SA.

Respirology. 2011 Aug;16(6):891-9. doi: 10.1111/j.1440-1843.2011.02011.x. Review.

PMID:
21672085
24.

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC.

25.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group.

Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.

PMID:
21571362
26.

Diagnostic value of N-terminal pro-brain natriuretic peptide in pleural effusions of cardiac origin.

Valdés L, José ES, Pose A, González-Barcala FJ, Alvarez-Dobaño JM, Ferreiro L, Anchorena C, Pereyra MF, González-Juanatey JR, Sahn SA.

Arch Bronconeumol. 2011 May;47(5):246-51. doi: 10.1016/j.arbres.2011.02.004. Epub 2011 Apr 6. English, Spanish.

27.

Pleural fluid analysis and radiographic, sonographic, and echocardiographic characteristics of hepatic hydrothorax.

Gurung P, Goldblatt M, Huggins JT, Doelken P, Nietert PJ, Sahn SA.

Chest. 2011 Aug;140(2):448-453. doi: 10.1378/chest.10-2134. Epub 2011 Jan 27.

28.

Pleural diseases.

Sahn SA.

Semin Respir Crit Care Med. 2010 Dec;31(6):647-8. doi: 10.1055/s-0030-1269825. Epub 2011 Jan 6. No abstract available.

PMID:
21213197
29.

The unexpandable lung.

Huggins JT, Doelken P, Sahn SA.

F1000 Med Rep. 2010 Oct 21;2:77. doi: 10.3410/M2-77.

30.

Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7. doi: 10.1164/rccm.201007-1179OC. Epub 2010 Dec 3.

31.

Diagnosing tuberculous pleural effusion using clinical data and pleural fluid analysis A study of patients less than 40 years-old in an area with a high incidence of tuberculosis.

Valdés L, San José ME, Pose A, Gude F, González-Barcala FJ, Alvarez-Dobaño JM, Sahn SA.

Respir Med. 2010 Aug;104(8):1211-7. doi: 10.1016/j.rmed.2010.02.025. Epub 2010 Mar 26.

32.

Dasatinib-induced pleural effusions: a lymphatic network disorder?

Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA.

Am J Med Sci. 2009 Nov;338(5):414-7. doi: 10.1097/MAJ.0b013e3181ae9227.

PMID:
19838099
33.

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.

King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM; INSPIRE Study Group.

Lancet. 2009 Jul 18;374(9685):222-8. doi: 10.1016/S0140-6736(09)60551-1. Epub 2009 Jun 29.

PMID:
19570573
34.

Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature.

Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, Casciola-Rosen L, Hong G, Dellaripa PF, Highland KB.

Chest. 2009 Jun;135(6):1550-1556. doi: 10.1378/chest.08-2233. Epub 2009 Feb 18. Review.

PMID:
19225060
35.

Chronic dyspnea and severe obstruction after pneumonectomy: postpneumonectomy syndrome.

Kalluri M, Sahn SA, Highland KB.

Am J Med Sci. 2008 Dec;336(6):530-1. doi: 10.1097/MAJ.0b013e31816740f9.

PMID:
19092332
36.

Pleural fluid analysis in chylous pleural effusion.

Agrawal V, Doelken P, Sahn SA.

Chest. 2008 Jun;133(6):1436-1441. doi: 10.1378/chest.07-2232. Epub 2008 Mar 13.

PMID:
18339791
37.

Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.

Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA.

COPD. 2008 Feb;5(1):25-34. doi: 10.1080/15412550701816187.

PMID:
18259972
38.

Common problems in critically ill obstetric patients, with an emphasis on pharmacotherapy.

Ko R, Mazur JE, Pastis NJ, Chang E, Sahn SA, Boylan AM.

Am J Med Sci. 2008 Jan;335(1):65-70. doi: 10.1097/MAJ.0b013e31815f1e14. Review.

PMID:
18195587
39.

Lipid pleural effusions.

Agrawal V, Sahn SA.

Am J Med Sci. 2008 Jan;335(1):16-20. doi: 10.1097/MAJ.0b013e31815d2634. Review.

PMID:
18195578
40.

The value of pleural fluid analysis.

Sahn SA.

Am J Med Sci. 2008 Jan;335(1):7-15. doi: 10.1097/MAJ.0b013e31815d25e6. Review.

PMID:
18195577
41.

An update in pulmonary and critical care medicine. Preface.

Sahn SA.

Am J Med Sci. 2008 Jan;335(1):1. doi: 10.1097/MAJ.0b013e31815d2a1d. No abstract available.

PMID:
18195575
42.

Diagnosis and management of parapneumonic effusions and empyema.

Sahn SA.

Clin Infect Dis. 2007 Dec 1;45(11):1480-6. Epub 2007 Oct 24.

PMID:
17990232
43.

Seat belt-induced chylothorax: a cause of idiopathic chylothorax?

Agrawal V, Doelken P, Sahn SA.

Chest. 2007 Aug;132(2):690-2.

PMID:
17699142
44.
45.

Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature.

Bullington W, Sahn SA, Judson MA.

Am J Med Sci. 2007 May;333(5):290-2.

PMID:
17505171
46.

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.

Clin Ther. 2007 Feb;29(2):261-78.

PMID:
17472819
47.

Diagnosis and treatment of tuberculous pleural effusion in 2006.

Gopi A, Madhavan SM, Sharma SK, Sahn SA.

Chest. 2007 Mar;131(3):880-889. doi: 10.1378/chest.06-2063. Review.

PMID:
17356108
48.

Unusual presentations of pulmonary sarcoidosis: cases from the medical university of South Carolina.

Judson MA, Vincent B, Huggins T, Silvestri GA, Sahn SA.

Semin Respir Crit Care Med. 2007 Feb;28(1):75-82.

PMID:
17330193
49.

Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT.

Huggins JT, Sahn SA, Heidecker J, Ravenel JG, Doelken P.

Chest. 2007 Jan;131(1):206-13.

PMID:
17218577
50.

Supplemental Content

Support Center